Hypofractionated Radiotherapy for Lung Cancer

Completed · Phase 1

Conditions studied: Lung Cancer

In brief

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Key facts

Study ID

NCT00214123

Run by

University of Wisconsin, Madison

People needed

79

Starts

2004-06-01

Expected to finish

2012-12-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

You may not qualify if…

• Prior bleomycin or gemcitabine chemotherapy
• Prior thoracic radiotherapy

Where it is running

• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.